Shots:
- Artiva to receive $30M up front for the first 2 programs & an additional $15M, if Merck exercises its option for a third program. Artiva to get ~$612M/ program as development & commercial milestones and royalties on the global sales of the product emerge from the collaboration
- Artiva receives funding from Merck for each of its programs. The collaboration utilizes Artiva’s off-the-shelf allogeneic NK cell and CAR technology platforms to develop ~ three CAR-NK cell therapies targeting solid tumor-associated antigens
- Artiva will develop the CAR-NK programs through the first GMP manufacturing campaign and IND preparation and will transfer to Merck for clinical and commercial development
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Merck Signs an Exclusive Worldwide License Agreement with Artiva to Develop CAR-NK Cell Therapies first appeared on PharmaShots.
